PLX - Protalix BioTherapeutics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/2015
Total Revenue19,2429,1994,364
Cost of Revenue15,2318,398730
Gross Profit4,0118013,634
Operating Expenses
Research Development28,83424,60820,025
Selling General and Administrative11,5309,3567,279
Non Recurring---
Others---
Total Operating Expenses---
Operating Income or Loss-36,353-33,163-23,670
Income from Continuing Operations
Total Other Income/Expenses Net-39,1988,179123
Earnings Before Interest and Taxes-75,551-24,984-23,547
Interest Expense9,7254,1923,735
Income Before Tax-85,276-29,176-27,282
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-85,276-29,176-27,282
Non-recurring Events
Discontinued Operations--18985,319
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-85,276-29,36558,037
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-85,276-29,36558,037